Aim: Homocysteine (Hcy) is a sensitive marker of one-carbon metabolism. Higher Hcy levels have been associated with global DNA hypomethylation. We investigated the association between plasma Hcy and epigenome-wide DNA methylation in leukocytes. Methods: Methylation was measured using Illumina 450 k arrays in 2035 individuals from six cohorts. Hcy-associated differentially methylated positions and regions were identified using metaanalysis. Results: Three differentially methylated positions cg21607669 (SLC27A1), cg26382848 (AJUBA) and cg10701000 (KCNMA1) at chromosome 19, 14 and 10, respectively, were significantly associated with Hcy. In addition, we identified 68 Hcyassociated differentially methylated regions, the most significant of which was a 1.8-kb spanning domain (TNXB/ATF6B) at chromosome 6. Conclusion: We identified novel epigenetic loci associated with Hcy levels, of which specific role needs to be further validated.
Homocysteine (Hcy), an intermediate of the one-carbon metabolism, is an independent risk factor of diseases like osteoporotic fractures [1] and cardiovascular disorders [2] . In addition, Hcy is often used as sensitive marker of folate-and vitamin B12 deficiency. Recent intervention trials were not able to show that lowering of plasma Hcy by B-vitamin intervention led to a reduction in disease risk such as myocardial infarction [3] [4] [5] and osteoporotic fractures [6] . Identification of the underlying pathophysiological mechanism of Hcy is warranted to understand its role as biomarker of several disease states.
Hcy is formed by a demethylation reaction from methionine. In the methionine cycle, sadenosylmethionine donates its methyl group to the DNA resulting in sadenosylhomocysteine (SAH) as a by-product and a potent inhibitor of this methyltransferase reaction. SAH is hydrolyzed to Hcy in a reversible manner. Elevated Hcy in a condition known as hyperhomocysteinemia (HHcy) is associated to and increased SAH level, which is linked to alterations in DNA methylation [7] [8] [9] . This is one of the possible mechanisms in Hcy-related pathologies and the rational to study the effect of Hcy on genome-wide DNA methylation.
Hcy is a sensitive marker of one-carbon metabolism and will increase when remethylation or trans-sulfuration is impaired. Shortage of folate, vitamin B12 or B6 results in elevated Hcy levels. Although folate levels are important, we believe that it is not necessary to correct for folate in our analysis as Hcy is strongly correlated to folate and belongs to the same pathway. This would have canceled out the effect of Hcy itself on DNA methylation. The general hypothesis of this study was that Hcy is associated with changes in DNA methylation irrespective of the cause.
Normal circulating Hcy levels range from 8 to 10 μmol/l for women and 10 to 12 μmol/l for men [10] . Mild or moderate HHcy is referred to Hcy concentrations between 15 and 30 μmol/l, whereas intermediate and severe HHcy is referred to Hcy concentrations between 30-100 and >100 μmol/l, respectively [10] [11] [12] . HHcy has been shown to be associated with both global-and gene-specific DNA hypomethylation, which was recently reviewed by us [14] . In candidate gene studies of animal models, genes whose methylation have shown association with Hcy are the hypomethylation of imprinted genes (e.g., IGF2/H19 locus) [19, 20] , cardiac Trp53 [21] , leukocytic mTERT promoter [22] , brain Nr3c1 exon region [17] , brain Ppp2r1a [23] and liver 5′-portion of Soat2 [24] and hypermethylation of the aortic Nr3c1 promoter [25] and liver Fads2 promoter [26] . In human studies, HHcy has been shown to be associated with altered methylation of the RFC1 gene [27] . For patients with vascular disorders, HHcy has shown association with hypomethylation of the leukocytic hTERT promoter [22] , leukocytic SHC1 promoter [28] , punch aortic NOS2 proximal promoter [29] and hypermethylation of the blood ESR1 promoter [30] and internal mammary artery NOS2 proximal promoter [29] . For patients with colorectal, esophageal and breast cancer, HHcy has shown association with hypermethylation of ESR1 promoter [31] and exon 1 [32] , MLH1 promoter [33] , RARB promoter exon [32] , BRCA1 and RASSF1 promoter [34] .
In animal models, HHcy was also shown to associate with global hypomethylation [15] [16] [17] [18] . Human studies included mostly small-scale studies in renal or vascular patients with HHcy in which global DNA hypomethylation was observed [10, 13, 35] . Most studies showed significant associations of Hcy with DNA methylation, however, also null associations have been found [36, 37] . Hence, the association between Hcy and DNA methylation is complex, contradictory and remains to be fully understood. Mild HHcy can occur due to either genetic or environmental factors such as low intake of B vitamins. Regardless of the cause, Hcy itself is thought to be the most prominent key player in altering DNA methylation patterns and associated disease risks.
In the current manuscript, we explored the association of Hcy in relation to genome-wide CpG site level in leukocytes to assess its role in DNA methylation. In this study, we performed a meta-analysis in 2035 individuals of six individual cohorts using the highresolution Infinium Illumina 450 k BeadChip arrays.
Materials & methods

Cohorts
Six cohorts participated in the analysis, Rotterdam study [38] (n = 700), Leiden Longevity study [39] (n = 550), Cohort on Diabetes and Atherosclerosis Maastricht [40] (n = 186), MARseille THrombosis Association study [41] (n = 293), Estonian Biobank [42] (n = 96) and French-Canadian family study on Factor V Leiden thrombophilia [41] (n = 210). This added up to a total sample size of 2035 for the meta-analysis. The ethics review committees approved each study at their relevant organizations. Characteristics of each study are provided in Table 1 and Supplementary Text 1. 
Hcy measurements
Total Hcy was measured in ethylenediaminetetraacetic acid plasma. Measurements in nonfasting state were performed in the Leiden Longevity study and Estonian Biobank study, while rest of the studies measured Hcy in fasting state. Details of each method are depicted in Table 1 . Since the absolute values of Hcy in all studies were skewed to the right, logarithmic transformation of base 10 was used to achieve normal distribution. For a sample to be considered as an outlier, an outlier detection strategy [43] was used with four parameters of the Hcy log10 transformed data: quartile 1 (Q1), quartile 3 (Q3), interquartile range (IQR) and a multiplying factor (M). The lower end outliers (LO) were detected by the formula, LO = Q1 -(M*IQR), and upper end outliers (UO) were detected using UO = Q3 + (M*IQR). Any value less than or equal to LO and greater than or equal to UO was considered as an extreme outlier, using the M 3. A logarithmic transformation of base 10 and removal of outliers showed a clear improvement toward normal distribution ( Supplementary Figure 1 ).
DNA methylation assessment
Genomic DNA was extracted from whole blood and was bisulfite converted. Infinium Illumina HumanMethylation 450k BeadChip arrays (Illumina, Inc., CA, USA) were used to perform DNA methylation profiling according to the manufacturers' protocol. This assay covers methylation status of a wide range of CpGs at more than 450,000 sites at regions of CpG islands, shores and shelves. The sites annotate to various gene regions like promoters, enhancers, gene bodies, exons and UTRs [44] . Standard β-values were considered for the methylation analysis in all studies. These contain values ranging from 0 to 1, representing the percentage of methylation. β-values are calculated from the methylated (m) and unmethylated (u) probe intensities using the formula of β = m/(m + u + α), with the default alpha (α) of 100. These values were normalized using methods, such as DASEN [45] or SWAN [46] . Details of DNA methylation assessment, preprocessing methods and sample and probe quality control used by each cohort are provided in Supplementary Text 1 and Supplementary Table 1 .
Differentially methylated positions
Statistical analysis to identify differentially methylated positions (DMPs) was performed using R programming scripts, which were send around to each cohort and run by each cohort separately with log10 transformed Hcy as the exposure variable and DNA methylation as an outcome. This association analysis was performed using linear-mixed models of the lme4 package in R. The association model was adjusted for technical covariates and biological covariates like age, sex and differential white blood cell counts. Array number and position on array were used as technical covariates, and were treated as random effects. For cohorts that did not contain measured white blood cell counts, the counts were inferred using the Houseman method as implemented in the minfi package [47] (Table 1) .
Association analyses provided summary statistics from each study. A fixed effect metaanalysis was performed in 2035 individuals of six cohorts using the classical approach of the METAL software [48] that combines effect size estimates and standard errors of each study summary statistics. Probes with SNPs at single-base extension site were removed to avoid confounding and spurious signals. Probes with improper binding were also removed to avoid cohybridization with alternate homologous sequences [49] . In addition, we removed probes that were present in less than four studies since each cohort had different probe exclusions. This resulted in 468,108 probes remaining. The Benjamini-Hochberg (BH) method was used to define statistical significance for a false discovery rate (FDR) less than 0.05. The genomic inflation factor (λ) was calculated [50] and cohort heterogeneity was considered by taking into account the heterogeneity I 2 parameter [48] . CpGs for nearby genes were annotated using the Genomic Regions Enrichment of Annotations Tool [51] . This assigns extension up to 5-kb upstream and 1-kb downstream to a basal regulatory region from its transcription start site and a maximum up to 1-Mb extension distance, as defined by UCSC [52] .
IGF2/H19 locus
We also looked up for the three differentially methylated regions (DMRs) of IGF2/H19 locus at chromosome 11, which were previously related with Hcy [19, 20] . The seven 450 k array CpGs underlying the three DMRs of this locus were identified using the literature [36, 53, 54] . Multiple testing using the Bonferroni method was applied on these seven CpGs to test for their significance with Hcy.
Enrichment of previously found folate-associated CpGs
Because Hcy is associated with folate, we additionally focused our analysis on the previously found 443 CpGs in cord blood of newborns associated with maternal plasma folate during pregnancy [55] . In order to check for their significant enrichment, we compared their p-values with the p-values of randomly selected 443 CpGs from the array, using the Fisher's exact test.
Differentially methylated regions
DMRs were identified using the python library of the comb-p software [56] . Absolute pvalues from the meta-analysis of DMP analysis were given as input to combine them [57] adjacently at varying distance lags of 50 base pairs (bp) in a sliding-window of 500 bp, in order to calculate autocorrelation between them. As weighted according to this autocorrelation, each p-value is adjusted according to its adjacent p-values. An FDR correction using the BH method is then calculated on these adjusted p-values. A peak-finding algorithm then finds enrichment regions on these FDR-corrected adjusted p-values, and using Stouffer-Liptak correction as implemented in comb-p [56, 58, 59] , it then assigns new p-values to the identified regions using the original absolute p-values from the meta-analysis. Finally, these assigned new p-values of the identified regions are multiple tested using the Sidak correction [60] , where the defined statistical significance for the identified regions was Sidakcorrected P less than 0.05. The number of tests for a region in the Sidak correction is the total bases covered by input probes divided by the region size [56] .
DMRs: pathway analysis
For the pathway analysis, we annotated the regions for genes using the Genomic Regions Enrichment of Annotations Tool [51] . We used WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) [61] online resource for pathway analysis. KEGG database were used for enrichment. The BH method in WebGestalt was used to define statistical significance for an FDR less than 0.05.
Results
Cohort characteristics
Meta-analysis comprised of six cohorts with a total of 2035 individuals. All individuals were of European ancestry. The study design was mainly population based but also included cohorts with increased risk of diabetes, cardiovascular disorders and venous thromboembolism. Study characteristics for all the participating cohorts are given in Table 1 .
Differentially methylated positions
Meta-analysis on 468,108 CpGs was done on the summary statistic of the six cohorts (Supplementary Figure 2) comprising of 2035 individuals. The p-values of this analysis showed a genomic inflation factor of 1.2 ( Supplementary Figure 3 ). Three DMPs (Table 2 & Figure 1 ) were significantly associated with Hcy (FDR < 0.05). All three DMPs showed 1% increase in methylation with each unit increase in the 10 logarithmic Hcy value. The DMP cg21607669 located near the gene SLC27A1 at chromosome 19 had the lowest p-value of 7.71 × 10 -8 (FDR = 0.04). The two other DMPs were cg26382848 (nearest gene AJUBA) located at chromosome 14 with p-value 1.67 × 10 -7 (FDR = 0.04) and cg10701000 (nearest gene KCNMA1) located at chromosome 10 with p-value 2.38 × 10 -7 (FDR = 0.04). These three DMPs showed no substantial cohort heterogeneity I 2 (I 2 < 35). The direction of effects were mostly similar between all studies (Figure 2A -C). Nearest genes for these three DMPs are reported.
DMP: Differentially methylated position. 
IGF2/H19 locus
We did a lookup for CpGs at the three DMRs of the IGF2/H19 gene (DMR0, DMR2, H19-DMR3) that have been previously studied in humans [36, 53, 54] . Data from our 450 k arrays contained seven CpGs at these DMRs: two at DMR0, four at DMR2 and one at H19-DMR3. However, none of the seven CpGs showed an association with Hcy with a Bonferroni cutoff of 7.14 × 10 -3 (Table 3 & Supplementary Figure 5 ). 
Enrichment of previously found folate-associated CpGs
For the previously found 443 CpGs in cord blood of newborns associated with maternal plasma folate during pregnancy [55] , we compared their nominal p-values with 443 randomly selected CpGs in the array using 100 permutations. Based on our significant threshold (p < 0.05), 20 of the 443 folate-related CpGs met the threshold as compared with the 32 of the 443 randomly selected CpGs in the array. Using the Fisher's exact test, we found no significant enrichment (p-value = 0.97) in the folate-related CpGs.
Differentially methylated regions
We identified 68 DMRs significant at Sidak P less than 0.05 ( Table 4 , Figure 3 & Supplementary Figure 4 ). The most significant was the DMR at chromosome 6 (spanning a region of 1.8 kb) with a p-value of 4.34 × 10 -24 (Sidak-P = 1.12 × 10 -21 ) containing 55 CpGs. CpGs within this region were annotated to gene TNXB and ATF6B. Pathway analysis on the 114 genes annotated to the 68 DMRs showed 14 significant pathways ( Table 5 ). Top five pathways were metabolic pathways, folate biosynthesis, glycosaminoglycan biosynthesisheparan sulfate, phagosome and MAPK signaling pathway. Furthermore, results of the GO enrichment analysis showed that many biological processes are related to embryogenesis and development ( Table 6 ). GO: Gene ontology.
Discussion
This is the first large-scale epigenome-wide site-specific collaborative meta-analysis studying the relationship between plasma Hcy levels and methylation at a genome-wide level. Our results show that plasma Hcy concentrations were associated with three DMPs and 68 DMRs. Identification of this relatively low number of DMPs is surprising, given the central role of Hcy in the methylation cycle.
The most significant of the three DMPs, cg21607669 is located at chromosome 19 near the promoter region of the gene SLC27A1 (+40 bp downstream). SLC27A1 assists in the transport of fatty acids across cell membrane, and its highest levels are found in muscle and adipose tissue [62] . Results from a recent meta-analysis demonstrated that omega-3 polyunsaturated fatty acid supplementation was associated with Hcy lowering [63] . It was hypothesized that the omega-3 fatty acid, docosahexaenoic acid upregulates metabolic enzymes of the onecarbon pathway like MAT resulting in increased s-adenosylmethionine bioavailability [63] . The exact role of hypermethylation of SLC27A1 should be further investigated to understand its possible role in the relation between polyunsaturated fatty acids and HHcy.
The second significant DMP, cg26382848 is located at chromosome 14 near the promoter region of the gene AJUBA (-39 bp upstream). AJUBA plays a role in cellular processes such as cell migration, proliferation and differentiation [64, 65] . It functions as a negative regulator of the retinoic signaling [66] and Hippo signaling pathway [67] , and is involved in tumors [68] .
However, the precise role of this gene is less clear and future replication studies are necessary to establish the role of this gene in relation to Hcy.
The third significant DMP, cg10701000 at chromosome 10 annotated to the nearby gene KCNMA1 (-143,626 bp upstream). KCNMA1 is a potassium calcium-activated channel and has its prominent role in many physiological processes of smooth muscles, hair cells and diseases of nervous system and cancer [69] . A recent study has shown that elevated cellular Hcy increases the activity of potassium calcium-activated channel in GH3 pituitary cells [70] , while two other previous studies have reported that Hcy inhibits these channels of artery smooth muscle cells [71, 72] . Our finding of hypermethylation near the KCNMA1 gene supports the involvement of Hcy in potassium calcium-activated channel.
We specifically studied the IGF2/H19 locus, the most frequently studied locus in relation to Hcy levels, and found that none of the CpGs on the array that were annotated to this locus showed an association with Hcy. We could therefore not corroborate results from two earlier studies that did find a relationship between Hcy levels and methylation at the IGF2/H19 locus [19, 20] . The reason could be that these studies were performed in HHcy mice models with heterogeneous knockout of the CBS gene, fed with high methionine and low folate diet. CBS deficiency is an inborn error of metabolism that leads to Hcy concentrations much higher at intermediate to severe levels, as compared with the ones present in our study. Furthermore, in human studies of patients with HHcy and uremia, the influence of Hcy on H19 methylation is also observed at a concentration of Hcy much higher at intermediate levels, as compared with the mild levels present in our study, and the monoallelic expression of H19 is shown to be reversed by folate supplementation [10] . Therefore, our results cannot be directly extrapolated in other populations where Hcy is higher especially in chronic renal failure and rare diseases of metabolism. However, our results are in line with another human study which did not find differences in intermediate HHcy patients with CBS deficiency and controls [36] . These patients were under Hcy-lowering therapy, which would have prevented the association with H19 DMR. Therefore, mildly elevated Hcy levels do not seem to be related to differences in methylation of the IGF2/H19 region in circulating leukocytes. Furthermore, focusing our analysis on the previously found CpGs in newborns in relation to maternal plasma folate during pregnancy, we did not find significant enrichment. We expected some enrichment because of the strong association of Hcy with folate. The reason for not finding enrichment could be related to the different study design of mother-offspring relationship compared with population-based cohorts.
Regional analysis using the comb-p software identified 68 DMRs significant at Sidak-P less than 0.05. The most significant was 1.8-kb DMR located at chromosome 6 spanning 55 CpGs. This DMR was annotated to the genes TNXB and ATF6B. TNXB is located within the class III region of the major histocompatibility complex [73] that had multiple CpG sites previously shown to be hypermethylated in anorexia nervosa patients compared with controls [74, 75] . Another gene located near this DMR is the ATF6B gene. This gene is involved in the unfolded protein response during endoplasmic reticulum stress and has been shown to be activated upon Hcy treatment to human endothelial cells [76] . More specifically a putative ATF6binding motif was identified, which was shown to be demethylated upon treatment with Hcy, which supports our findings of possible involvement of altered methylation of ATF6B in relation to HHcy. [55] . These regions are promising to be replicated in future studies.
DMR analysis is recommended as a part of the analysis pipeline in addition to CpG site analysis [82, 83] . It has been shown that methylation is regulated in genomic regions, which merits the identification of DMRs in addition to single CpGs. Several software packages are available to perform DMR analysis, with their own strengths and weaknesses (i.e., Bumphunter, DMRcate) [84] . In this paper, we applied comb-p that constructs regions based on the autocorrelation between the p-values at varying lags in a sliding window, which is a good approach for the unevenly spaced CpGs in the 450 k array [56] . A recent paper has shown that comb-p has good sensitivity. However, if the data signal is weak, comb-p has the tendency to return false-positives particularly in presence of low effect size [85] . We, therefore, decided to check the DMR results of comb-p in the Rotterdam study subset of 700 individuals, and compare them with the DMR results of another package, DMRcate [84] . Of the 49 significant DMRs within the subset of 700 individuals we found using comb-p package, we saw an overlap of 60%, with the DMRs found using DMRcate (data not shown).
Results of comp-b seem valid but further studies are also necessary to validate these findings further.
Pathway analysis on the 114 genes annotated to the 68 DMRs identified pathways related to metabolism such as folate biosynthesis, glycosaminoglycan biosynthesis, arachidonic acid metabolism and glycerophospholipid metabolism. This could suggest how elevated Hcy can affect other important pathways via DNA methylation impairment. Folate pathways contained two genes: ALPPL2 and ALPP. An important paralog of these genes, which is ALPL, previously showed polymorphisms that were associated with vitamin B6 that suggests its possible role in vitamin B6 catabolism [86] . However, these genes need to be further replicated because of its low number in the pathway. Results of the GO enrichment analysis showed many biological processes related to embryogenesis and development, where Hcy has most variedly shown to play a role by previous studies.
Most of the studies until now investigated this association by measuring DNA methylation at a global level. The strength of our study is that the association of mild HHcy with genomewide DNA methylation using 450 k arrays was studied. Second, this is the largest epigenomewide association study on Hcy including 2035 individuals.
Limitations of our study are that clinical heterogeneity between cohorts may have prevented us of finding additional true significant associations. Cohorts were either population based, or cases with venous thromboembolism, or have a mildly increased risk to develop Type 2 diabetes and/or cardiovascular disease. Hcy concentrations and related mechanisms may vary with such different pathophysiologies [87] . Furthermore, Hcy median concentrations were generally low in each cohort, with only 10.2-32.3% of individuals in the mild HHcy range more than 15 μmol/l (Table 1) , which could explain the subtle findings. Second, we acknowledge that Hcy levels were measured using different techniques in each study, either in fasting or nonfasting state, as well as there were differences in sample collections per cohort. However, the methylation analyses were done in each cohort separately, and the results of each separate study were then meta-analyzed. Our results are therefore not biased by the differences in Hcy measurement methods, state of fasting or sample collection. Nevertheless, this heterogeneity across cohorts could have resulted in null findings. Third, we did not account for differences in nutritional folate and/or vitamin B12 intake and B-vitamin supplementation, or Hcy-related diseases like renal insufficiency that could have confounded the results of our study [87] . We also did not account for the genetic background of individuals, especially methylenetetrahydrofolate reductase (MTHFR) 677C >T that is associated with Hcy [88] . We could have accounted for these confounding factors, but not all of these data were available to us. In addition, these confounding factors like folate, vitamin B12 and MTHFR 677C >T belong to the same pathway and are highly correlated with Hcy. This would have cancelled out the effect of Hcy itself on DNA methylation. We had hypothesized that Hcy is associated with DNA methylation regardless of the cause. However, adjusting for MTHFR 677C >T in the linear-mixed model analysis in Rotterdam study-III and Cohort on Diabetes and Atherosclerosis Maastricht did not change the findings (data not shown). Fourth, we did not account for population stratification in the methylation analysis of each cohort because all individuals were of European ancestry. But in order to check the influence of this, we reran the analysis only in the Rotterdam study by additionally adjusting for four genetic principal components (PCs). The results still showed no significant DMPs (FDR < 0.05). In addition, the three significant DMPs of meta-analysis showed same direction of effects with and without the four genetic PCs correction (Supplementary Figure 6) . Therefore, adding additional genetic PCs as covariates did not seem necessary and moreover, would reduce statistical power. Fifth, Hcy effect could be exclusive to certain other tissues like heart, liver and brain. Future studies still need to explore such findings. And lastly, even though we included 2035 individuals from all the possible studies to our knowledge who had Hcy and DNA methylation data measured at the same time point, statistical power might still be low to identify significant DMP signals. As such, replication was not easily tractable, a main limitation of our results.
Conclusion
Our meta-analysis showed three DMPs at chromosome 19, 14 and 10 with nearby genes of SLC27A1 and AJUBA, and 68 DMRs associated with Hcy concentrations. Knowing the prominent role of Hcy in donation of methyl groups, we expected to find more DMPs. However, DMR analysis does show promising findings, but their role in relation to onecarbon metabolism needs to be further investigated.
Summary points
• Plasma homocysteine is significantly associated with a modest number of differentially methylated positions in leukocyte DNA. • Sixty-eight differentially methylated regions related to 114 genes were significantly associated with plasma homocysteine. These genes were involved in folate biosynthesis, glycosaminoglycan biosynthesis, arachidonic acid metabolism and glycerophospholipid metabolism.
